BPS Bioscience

Executive Summary

BPS Bioscience is a San Diego-based private company established in 2010, specializing in the production of cell lines, proteins, assay kits, and lentiviruses for biological research. The company positions itself as a U.S.-made supplier for the drug discovery industry, offering custom protein expression, cell line development, and screening services to support preclinical programs across therapeutic areas including oncology, immunology, and infectious diseases. With a diversified product portfolio spanning antibodies, diagnostics, and drug delivery tools, BPS Bioscience serves pharmaceutical, biotech, and academic labs globally. Its emphasis on in-house manufacturing and quality control provides a competitive edge in the rapidly growing outsourced research tools market, which is driven by increasing R&D investments in biologics and targeted therapies. As a service-oriented supplier rather than a therapeutic developer, BPS Bioscience generates recurring revenue and avoids the binary risk of clinical-stage pipelines. However, its growth potential is tied to the overall health of drug discovery spending and its ability to innovate with new assay formats and reagents. The company’s lack of disclosed funding or valuation suggests it may be bootstrapped or privately funded, limiting visibility into financial performance. Nevertheless, its established presence in the biotech hub of San Diego and alignment with trends like personalized medicine and cell and gene therapy underpins a steady but unspectacular growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation PROTAC assay kits65% success
• Q4 2026Strategic partnership with a top-20 pharma for custom cell line development services60% success
• Q2 2027Expansion of lentiviral vector production capacity to meet gene therapy demand70% success